Kancera
Verified IntelKancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls immune cells and cancer cells with precision and therefore can play a crucial role to treat acute excessive inflammation and treatment resistant cancers. Kancera's lead drug candidate KAND567 is currently studied in a phase II trial to address the cardiac-protective effect of KAND567 following myocardial infarction. Kancera has also announced its intention to start a phase I/II study of KAND567 in ovarian cancer in the beginning of 2023. The stock is traded on the Nasdaq First North Premier Growth Market.
Kancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls immune cells and cancer cells with precision and therefore can play a crucial role to treat acute excessive inflammation and treatment resistant cancers. Kancera's lead drug candidate KAND567 is currently studied in a phase II trial to address the cardiac-protective effect of KAND567 following myocardial infarction. Kancera has also announced its intention to start a phase I/II study of KAND567 in ovarian cancer in the beginning of 2023. The stock is traded on the Nasdaq First North Premier Growth Market.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Public Company
- Founded
- 2010
- Employee Bracket
- 1-10
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- Nanna Svarts väg 4 Solna
- City
- —
- Region / State
- —
- Postal Code
- 17165
- Country
- Sweden
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for Kancera.